Last updated: April 10, 2026
What is NUTROPIN AQ?
NUTROPIN AQ is a biosynthetic human growth hormone (hGH), produced by Eli Lilly and affiliated companies. It is indicated for pediatric growth failure, growth hormone deficiency in adults, and other approved uses. As a recombinant protein, it is administered via subcutaneous injection. NUTROPIN AQ is a biosimilar to Genentech's Nutropin.
Regulatory Status and Patent Landscape
Approval for NUTROPIN AQ occurred in multiple markets, including the U.S., Europe, and Asia, starting around 2002. The drug's patent protections varied by region but largely expired or are set to expire between 2022 and 2025, opening markets for biosimilar competition.
Patent Details
| Territory |
Original Patent Expiry |
Biosimilar Entry Year |
Notes |
| US |
2015 |
2018 |
Patent litigation delayed biosimilars. |
| EU |
2015 |
2018–2020 |
Patent cliffs enabled biosimilar development. |
| Japan |
2017 |
2020 |
Patent protections more recent. |
Market Size and Share
Global Growth
The global growth hormone market was valued at approximately USD 4.4 billion in 2021. It is projected to grow at a CAGR of 4.3% from 2022 to 2027, driven by rising pediatric cases of growth hormone deficiency and increased adult utilization.
Segments
- Pediatric growth failure: 55%
- Adult growth hormone deficiency: 35%
- Other indications (e.g., Turner syndrome, chronic kidney disease): 10%
Regional Breakdown
| Region |
Market Share (2021) |
CAGR (2022–2027) |
Key Drivers |
| North America |
50% |
4.2% |
Established healthcare system, high diagnosis rates. |
| Europe |
25% |
4.5% |
Slow but steady adoption, government reimbursement. |
| Asia-Pacific |
15% |
6.0% |
Growing awareness, increasing healthcare access. |
| Rest of World |
10% |
4.8% |
Emerging markets, lower penetration. |
Market Share of Biosimilars
Biosimilar versions of NUTROPIN AQ and similar drugs have entered various markets post-2018. Their market share is sparse but increasing, concentrated predominantly in Europe and Asia due to clinical adoption and regulatory approvals.
- In Europe, biosimilars captured approximately 20–25% of the growth hormone market by 2021.
- US biosimilar penetration remains limited, with less than 10% of prescriptions as of 2022.
Pricing and Reimbursement Trends
Price Trends
| Region |
Average Annual Cost (USD) |
Price Reduction Since Biosimilar Entry |
| US |
20,000–25,000 |
15–20% decline (2020–2022) |
| EU |
15,000–20,000 |
25–30% decline (post-biosimilar approval) |
| Japan |
18,000–22,000 |
10% decline (2021) |
Reimbursement Policies
- Payers are increasingly favoring biosimilars due to cost savings, with some countries implementing policies that incentivize biosimilar prescribing.
- US Medicaid programs have adopted policies favoring biosimilar substitution, impacting market dynamics.
Financial Trajectory and Forecast
Revenue Estimates
- Eli Lilly reported approximately USD 80 million in NUTROPIN AQ sales globally in 2021.
- Biosimilar entrants are expected to impact revenue, pushing growth downward as market share consolidates.
Projected Revenue Trends
| Year |
Estimated US Sales (USD)* |
Global Sales (USD) |
Comments |
| 2022 |
60–70 million |
75–90 million |
Biosimilar competition rising; price pressure persists. |
| 2025 |
50–60 million |
65–80 million |
Market consolidation; increased biosimilar penetration. |
| 2030 |
30–40 million |
45–60 million |
Biosimilar market stabilizes; innovation and new indications may sustain revenues. |
*Estimates based on current trends, patent expiries, competition levels, and pricing adjustments.
Competitive Landscape
Top competitors include:
- Genentech's Nutropin (original)
- Sandoz's Omnitrope (biosimilar)
- Pfizer's Dralimumab (biosimilar for other indications)
- Local biosimilar manufacturers in China, India, and Asia-Pacific
Market penetration by biosimilars is highest in Europe, where regulatory pathways are more mature. US market entry remains challenged by regulatory hurdles, payer hesitations, and patent litigation.
Key Drivers & Challenges
Drivers
- Patent expirations create biosimilar opportunities
- Rising diagnosis rates of growth hormone deficiency
- Cost pressures motivate biosimilar adoption
- Advances in biosimilar manufacturing technologies improve quality
Challenges
- Limited interchangeability policies in some regions
- Prescriber and patient perceptions of biosimilar efficacy
- Regulatory approval processes remain complex
- Price erosion due to competition
Conclusion
NUTROPIN AQ remains a significant player in growth hormone therapy but faces increasing biosimilar competition following patent expiries from 2018 onward. Market growth is driven by rising demand for hormone therapies and regulatory approvals of biosimilars. Revenue will likely decline due to price competition and market saturation, with growth concentrated in emerging markets and indications.
Key Takeaways
- The global growth hormone market is expanding, with biosimilars entering due to patent expirations.
- Biosimilar market share in Europe exceeds 20%, but US adoption remains limited.
- US sales of NUTROPIN AQ in 2021 reached approximately USD 80 million; future revenue will decline as biosimilars gain market share.
- Price reductions are observed across regions, especially post-biosimilar approval.
- The competitive landscape shifts toward biosimilar manufacturers, with more entrants expected in the next decade.
FAQs
-
When did biosimilars of NUTROPIN AQ enter the market?
Biosimilars began approved in Europe around 2018, with US approval following shortly after in 2018–2020.
-
What is the main factor driving biosimilar adoption?
Cost savings and patent expirations are primary factors. Payer policies favor biosimilars to reduce healthcare expenditures.
-
How will biosimilar competition affect future revenues?
Biosimilar entry is expected to reduce NUTROPIN AQ's market share and price, leading to lower revenues in mature markets.
-
Which regions are leading biosimilar adoption for growth hormone drugs?
Europe and Asia-Pacific are leading due to proactive regulatory frameworks and healthcare system demands.
-
What challenges inhibit biosimilar market penetration?
Regulatory complexity, prescriber skepticism, and limited interchangeability policies impede rapid adoption.
References
[1] MarketWatch. (2022). Growth hormone market report.
[2] EvaluatePharma. (2022). 2021 global biotech sales report.
[3] EMA. (2020). Biosimilar medicines’ regulatory pathway.
[4] IQVIA. (2022). Biosimilar market access and pricing analysis.
[5] U.S. FDA. (2021). Biosimilar development and approval process.
